Solid Biosciences Inc. Financing Cash Flow
Solid Biosciences Inc. (SLDB) reported Financing Cash Flow of $287.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Solid Biosciences Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $48.47M.
- Solid Biosciences Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $239.03M, a 25.98% increase year-over-year.
- Solid Biosciences Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $5.14M, a 25.89% decline year-over-year.
- Solid Biosciences Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.18M, a 63.88% decline year-over-year.
- Solid Biosciences Inc. net cash provided by (used in) financing activities for fiscal 2025 was $194.45M, a 58.81% increase from fiscal 2024.
- Solid Biosciences Inc. net cash provided by (used in) financing activities for fiscal 2024 was $122.44M, a 3821.75% increase from fiscal 2023.
- Solid Biosciences Inc. net cash provided by (used in) financing activities for fiscal 2023 was $3.12M, a 95.83% decline from fiscal 2022.
- Solid Biosciences Inc. net cash provided by (used in) financing activities for fiscal 2022 was $74.83M, a 44.56% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $48.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $287.50M 10-Q · filed 2026-08-06 | $292.64M derived: sum of 3 quarters · filed 2026-08-06 | $293.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $239.03M 10-Q · filed 2026-05-12 | $244.17M derived: sum of 2 quarters · filed 2026-05-12 | $245.35M derived: sum of 3 quarters · filed 2026-05-12 | $243.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $6.32M derived: sum of 2 quarters · filed 2026-03-19 | $4.72M derived: sum of 3 quarters · filed 2026-08-06 | $194.45M 10-K · filed 2026-03-19 |
| 2025-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$425.00K derived: sum of 2 quarters · filed 2026-08-06 | $189.30M 10-Q · filed 2025-11-03 | $196.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $188.13M 10-Q · filed 2026-08-06 | $195.07M derived: sum of 3 quarters · filed 2026-08-06 | $198.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $189.73M 10-Q · filed 2026-05-12 | $196.67M derived: sum of 2 quarters · filed 2026-05-12 | $199.92M derived: sum of 3 quarters · filed 2026-05-12 | $204.92M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $6.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $10.20M derived: sum of 2 quarters · filed 2026-03-19 | $15.20M derived: sum of 3 quarters · filed 2026-03-19 | $122.44M 10-K · filed 2026-03-19 |
| 2024-09-30 | $3.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $8.26M derived: sum of 2 quarters · filed 2025-11-03 | $115.50M 10-Q · filed 2025-11-03 | $116.00M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $112.24M 10-Q · filed 2025-08-12 | $112.75M derived: sum of 3 quarters · filed 2025-08-12 | $112.75M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $107.24M 10-Q · filed 2025-05-15 | $107.75M derived: sum of 2 quarters · filed 2025-05-15 | $107.75M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $505.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $505.00K derived: sum of 2 quarters · filed 2025-03-06 | $3.12M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.62M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $2.62M 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $74.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $74.74M derived: sum of 2 quarters · filed 2024-03-13 | $74.81M derived: sum of 3 quarters · filed 2024-03-13 | $74.83M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $72.00K derived: sum of 2 quarters · filed 2023-11-08 | $94.00K 10-Q · filed 2023-11-08 | $160.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $95.00K 10-Q · filed 2023-08-14 | $161.00K derived: sum of 3 quarters · filed 2024-03-13 | $164.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $22.00K 10-Q · filed 2023-05-11 | $88.00K derived: sum of 2 quarters · filed 2024-03-13 | $91.00K derived: sum of 3 quarters · filed 2024-03-13 | -$147.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $69.00K derived: sum of 2 quarters · filed 2024-03-13 | -$169.00K derived: sum of 3 quarters · filed 2024-03-13 | $134.99M 10-K · filed 2024-03-13 |
| 2021-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$235.00K derived: sum of 2 quarters · filed 2022-11-10 | $134.92M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $134.92M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $135.15M 10-Q · filed 2022-04-27 | |||
| 2020-12-31 | $128.70M 10-K · filed 2023-03-23 | |||
| 2019-12-31 | -$287.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $57.88M 10-K · filed 2022-03-14 | ||
| 2019-09-30 | $58.16M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | -$13.00K derived: sum of 2 quarters · filed 2021-03-15 | -$206.00K derived: sum of 3 quarters · filed 2021-03-15 | $131.51M 10-K · filed 2021-03-15 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$193.00K derived: sum of 2 quarters · filed 2019-11-12 | $131.52M 10-Q · filed 2019-11-12 | $185.28M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | -$193.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $131.52M 10-Q · filed 2019-08-14 | $185.28M derived: sum of 3 quarters · filed 2020-03-12 | $184.33M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $131.71M 10-Q · filed 2019-05-13 | $185.47M derived: sum of 2 quarters · filed 2020-03-12 | $184.53M derived: sum of 3 quarters · filed 2020-03-12 | $183.97M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $53.76M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $52.81M derived: sum of 2 quarters · filed 2020-03-12 | $52.26M derived: sum of 3 quarters · filed 2020-03-12 | $77.08M 10-K · filed 2020-03-12 |
| 2017-09-30 | -$943.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | -$1.50M derived: sum of 2 quarters · filed 2018-11-13 | $23.32M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | -$558.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $24.26M 10-Q · filed 2018-08-10 | ||
| 2017-03-31 | $24.82M 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | $3.42M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |